Key result
Unrestricted genetic testing detects breast cancer pathogenic variants in ~3% of women, supporting broader screening.
Why the study?
The population prevalence of pathogenic variants in breast cancer susceptibility genes remains largely unknown, partly because of restrictions in genetic testing guidelines.
Does unrestricted genetic testing identify pathogenic variants in women without breast cancer who would not qualify under standard guidelines?
Does unrestricted genetic testing identify pathogenic variants in women without breast cancer who would not qualify under standard guidelines?
Unrestricted genetic testing in women without breast cancer identifies a substantial number of pathogenic variants, including in 30% who lack traditional risk factors like family history.
No takes yet. Share an insight, caveat, or question.
Supports expanding genetic testing beyond family history criteria; extends RCT evidence for population-level breast cancer risk assessment.
Fergus et al. (2026) studied this question. Unrestricted genetic testing in 23,098 women found 3.1% carried breast cancer pathogenic variants; 30% had no family history or Jewish ancestry, supporting broader testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: